At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 46 enrolled
Drug / intervention
SUPLEXAbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1, First-in-Human, Open-label Single Agent Study of SUPLEXA Therapeutic Cells in Patients With Metastatic Solid Tumours and Haematologic Malignancies
In Brief
A Phase 1 clinical trial evaluating SUPLEXA for Oncology. Completed, enrolled 46 participants across 3 sites.
Detailed Summary
This Phase 1, first-in-human (FIH), open-label study is designed to assess the safety, tolerability, and preliminary clinical efficacy of repeated intravenous (IV) infusions of SUPLEXA monotherapy in subjects with measurable metastatic solid tumours and haematologic malignancies
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOncology
CountriesAustralia
Collaborators--
Timeline
Phase 1CompletedFinished
20222023202420252026
First PostedFeb 2022
Enrollment StartApr 2022
Primary CompletionJul 2024
TodayJul 2026
First PostedFeb 14, 2022
Enrollment StartApr 28, 2022
Primary CompletionJul 23, 2024
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 4.4 years ago
Interventions
SUPLEXAbiological
PBMC-derived autologous cellular therapy derived through an ex vivo activation procedure, resulting in a cell mixture comprised predominantly of NK, NK-T, and T cells stored in cryogenic media.